It's currently under consideration as a first-line treatment for advanced or metastatic malignant pleural mesothelioma, among ...

Well-differentiated papillary mesothelioma of the pleura is a rare variant in the spectrum of pleural neoplasmas. This disease has initially been described in the peritoneum of young women without ...

Credit: SewCreamStudio / Shutterstock. Moderna and MSD have initiated a Phase III clinical study to evaluate mRNA-4157 (V940), an investigational individualised neoantigen therapy, in combination with ...

in combination with Keytruda, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with resectable Stage II, IIIA or IIIB non-small cell lung cancer who did not achieve a pathological ...

The INTerpath-009 trial will investigate an individualized neoantigen therapy plus Keytruda in patients with non-small cell lung cancer post-surgery whose disease didn't fully respond to prior ...

NEW YORK – Moderna and Merck will test their personalized neoantigen cancer vaccine V940 with Merck's checkpoint inhibitor Keytruda (pembrolizumab) in certain non-small cell lung cancer patients in a ...

Mesothelioma is an aggressive tumor with a poor prognosis. Histological diagnosis of mesothelioma using limited tissue samples can be challenging. Carbonic anhydrase IX (CAIX) is a transmembrane ...

With these approvals, KEYTRUDA is now authorized for 30 indications in the EU, including five in gynecologic cancers, Merck said in a statement. RAHWAY: Merck, also known as MSD outside the US and ...

RAHWAY, N.J. - Merck, known as MSD outside the United States and Canada, has received approval from the European Commission (EC) for two new indications of its anti-PD-1 therapy, KEYTRUDA® ...

Merck’s (NYSE:MRK) blockbuster cancer therapy Keytruda (pembrolizumab) has been cleared by the European Commission to treat two new indications in gynecologic cancers. The first approval is for ...